HaystackAnalytics

One-Line Summary

HaystackAnalytics is a Mumbai-based clinical genomics HealthTech company developing next-generation sequencing (NGS)-based diagnostic products for infectious diseases, with a primary focus on tuberculosis and sepsis-causing pathogen identification for use by diagnostic laboratories and hospitals across India.

Company Description

HaystackAnalytics Private Limited is a clinical genomics product company founded and incubated at the Society for Innovation and Entrepreneurship (SINE), IIT Bombay, where it remains headquartered at the KReSIT Building, Powai, Mumbai. The company operates at the intersection of genomics, bioinformatics, and clinical diagnostics, with a stated mission of eliminating preventable deaths from infectious diseases through accurate, rapid, and culture-independent pathogen identification.

The company was founded by a multidisciplinary team combining deep expertise in genomics, molecular biology, infectious disease, and technology operations. Leadership comprises Dr Anirvan Chatterjee (CEO), who has over a decade of experience in NGS-based healthcare deployment at NHS UK and DTU Denmark; Gaurav Srivastava (COO), an IIT alumnus with operational experience across technology startups; and Prof. Kiran Kondabagil (Chief Scientific Member), Head of Biosciences at IIT Bombay with specialised expertise in molecular biology, infectious disease, and genomics.

HaystackAnalytics has received grant funding and institutional support from some of India’s most prominent scientific bodies, including the Department of Science and Technology (DST), the Biotechnology Industry Research Assistance Council (BIRAC), the Department of Biotechnology (DBT), and the Centre for Augmenting WAR with COVID-19 Health Crisis (CAWACH). The company’s tuberculosis genomics diagnostic was recognised as one of the top innovations supported by BIRAC over a ten-year period and was launched publicly by the Prime Minister of India at the BIRAC Biotech Startup Expo in Delhi in 2022. Additional recognition includes the Economic Times Tech Startup of the Year Award (Big Data category, 2022), the NASSCOM Most Innovative Startup Award (2019), the CAHOTECH Pitch Fest for Healthcare Startups (2022), and participation in the GE Healthcare Edison Programme.

The company’s commercial network spans over 100 cities, 100 hospitals, and 500 doctors across India, with named institutional partners including leading hospital networks and diagnostic laboratories.

Key Products and Services

Universal ID (UID) — Universal Infectious Diseases Test

• An NGS-based, culture-free diagnostic test for the identification of causative pathogens in patients with suspected sepsis or serious systemic infection
• Coverage of over 1,200 pathogens, including bacteria and fungi, within a single comprehensive screening test — significantly broader than conventional culture methods (limited to culturable organisms) and multiplex molecular panels (typically covering up to 43 pathogens)
• Antibiotic Resistance Gene (ARG) profiling, providing actionable drug resistance information to guide antimicrobial therapy selection
• Results reported in under 12 hours with hands-on laboratory time of under 4 hours, compared to 2–10 days for conventional culture methods
• Species and genus-level pathogen identification from clinical samples

ΩTB® — Tuberculosis Genomics Diagnostic

• NGS-based diagnostic product designed specifically for tuberculosis detection and characterisation
• Developed in response to India’s TB burden and the limitations of conventional TB diagnostics, including smear microscopy and culture-based methods
• Recognised by BIRAC as among India’s top biotech innovations of the past decade and endorsed at national government level

Identifi

• An additional clinical genomics diagnostic product within the HaystackAnalytics portfolio, details of which are available via the company’s website

HaystackAnalytics occupies a strategically significant position within India’s clinical diagnostics landscape, addressing two of the country’s most pressing infectious disease challenges — tuberculosis and sepsis — using a genomics-first diagnostic approach that offers material advantages over conventional culture-based and targeted molecular methods in terms of pathogen coverage, turnaround time, and resistance profiling. Its IIT Bombay institutional roots, multi-agency government grant backing, and national-level recognition provide a credibility foundation that is unusual for an early-stage diagnostic company. The Universal ID product’s coverage of over 1,200 pathogens in a single culture-free test positions it as a technically distinctive offering within the Indian in vitro diagnostics market, where culture methods remain the diagnostic standard of care for sepsis workup despite their well-documented limitations in turnaround time and sensitivity. The company’s commercial traction — with over 100 hospital partners across more than 100 Indian cities — indicates meaningful uptake beyond pilot or demonstration stage.